Instructions:

BEFORE YOU START: Review the draft document *Lung Transplant Referral for Individuals with cystic fibrosis: Cystic Fibrosis Foundation Consensus Guidelines*

SECTION 1: Demographics: Enter your role and association with the CF community

SECTION 2: General Feedback: Select your answer to the question, and then if directed, use the text box to provide additional information

SECTION 3: Recommendation Statement Feedback: Review the draft recommendation statements and associated supporting evidence and provide any comments

SECTION 4: Other Sections of the Manuscript Feedback: Use the text box to provide any additional comments on the other sections of the manuscript such as the introduction, methods, tables and figures, and international perspective

SECTION 5: Additional Feedback: Use the text box to provide any additional feedback that was not previously captured.
Lung Transplant Referral for Individuals with cystic fibrosis: Cystic Fibrosis Foundation Consensus Guidelines

Kathleen J. Ramos, Patrick J. Smith, Edward F. McKone, Joseph M. Pilewski, Amy Lucy, Sarah E. Hempstead, Erin Tallarico, Albert Faro, Daniel B. Rosenbluth, Alice L. Gray, and Jordan M. Dunitz for the CF Lung Transplant Referral Guidelines Committee

1. Introduction

Many individuals with cystic fibrosis (CF) die from respiratory failure without referral for lung transplantation (LTx)[1, 2]. LTx evaluation is best initiated for individuals with advanced but not end-stage lung disease; emergent inpatient referral does not allow time for careful consideration of the LTx option and is not universally available. Early referral for LTx gives individuals with CF the opportunity to learn more about the risks and benefits of LTx, both generally and specific to their clinical situation, so they can make informed decisions. Early referral for LTx evaluation increases the likelihood of an individual being a candidate for transplant by giving the patient an understanding of their specific barriers to LTx, as well as an opportunity to address those barriers. While some individuals who meet criteria for referral will be "too early" for listing, it is important to recognize that referral does not necessarily lead to a full evaluation or listing, but instead gives individuals with CF, their families, and providers access to the expertise of the LTx team. Progressing from routine CF care to LTx can be viewed as a transition. Just like the transition from pediatric to adult care, it is facilitated by education, communication and support for the individual and family. Timely referral for LTx allows individuals to be medically, psychosocially, and financially prepared for LTx should the need arise. While there may be not be a perfect "window" for referral, prioritizing inclusive policies reduces the likelihood that eligible patients miss an opportunity for LTx. The goal of these Consensus Guidelines is to provide pragmatic recommendations and guidance to the CF community to allow for better identification and timely referral of those individuals with CF who have advanced lung disease (ALD).

2. Methods

The CF Foundation invited a multidisciplinary team including adult and pediatric CF and transplant pulmonologists, a clinical psychologist, a social worker, a transplant recipient with CF, a former CF nurse, and a transplant coordinator to participate in development of consensus guidelines. The committee met for a virtual kickoff meeting on September 26, 2017 to determine the scope of the work and divide into three workgroups focusing on: understanding the timing for transplant referral; an emphasis on early referral and modifiable barriers; and transition to transplant. Several PICO (Population, Intervention, Control, Outcome) questions were developed. The workgroups performed individual literature searches in PubMed. Information about the specific literature searches can be found in Supplement X. The workgroups developed draft recommendations based on the results of the search. Workgroups discussed the recommendations on monthly phone calls. The committee reconvened on May 11, 2018 to revise and adopt the draft recommendation statements. An a priori voting threshold of 80% agreement was established. On September 19, 2018, the guidelines were distributed for public comment.

Focus Group
As part of the consensus guidelines, a focus group of seven CF transplant recipients and two spouses of recipients (hereafter referred to as “the focus group”) was organized. Although focus group content and data synthesis are qualitative in nature, these ancillary data sources can provide informative clinical data [3, 4]. The focus group participated in seven, one-hour long video-calls led by a transplant psychologist (PJS) and an adult with CF (AL). Following an introductory session during which thematic content was identified and analyzed, the focus group participated in five content-specific calls and one summary review call. Themes identified during the introductory call included: 1) timing of transplant information presentation, 2) transplant-related expectations, 3) treatment team transition issues, 4) stigma associated with the need for transplantation, and 5) concerns regarding social support during the transition to transplant. All calls were video- and audio-recorded in order to facilitate re-analysis by focus group leaders.

3. Discussion of Recommendation statements listed in Table 1

1. The CF Foundation recommends clinician-led efforts to normalize lung transplant as a component of clinical care through discussions regarding disease trajectory and treatment options including lung transplantation during annual clinic visits

For individuals with CF, post-transplant survival is increasing, with the current ISHLT report documenting 9.2 years median survival among adults with CF[5]; therefore, periodic discussion of LTx is recommended to help destigmatize the procedure. Numerous members of the focus group noted that early introduction and normalization of LTx facilitated a more effective transition/referral process. In contrast, when LTx was introduced in the context of clinical deterioration, it was associated with increased fear, denial, and potential delay and/or avoidance of important clinical elements of care. Many focus group members characterized their impressions of LTx as ‘a death sentence’, ‘the beginning of the end’, or with similarly negative connotations, despite the improving post-transplant survival outcomes (Table 2). It was also noted in the focus group that individuals’ feelings toward transplant strongly mirrored that of their physician(s). For example, a strong association was noted between physicians who reportedly exhibited a negative bias towards transplant and individuals who felt fear, anxiety, and a sense of personal failure. In contrast, individuals whose physicians reportedly regarded transplant more positively, and who approached transplant as a viable treatment option for end-stage CF, felt more informed, confident, and optimistic about their future quality of life. Several specific recommendations in the consensus guidelines may help accomplish the broader goal to normalize discussion of LTx, including earlier physician-patient discussions of LTx as a viable treatment option for end-stage CF, the use of up-to-date, understandable sources of information related to LTx [6, 7], and alternative discussion points for clinicians (Table 2).

2. The CF Foundation recommends CF care team initiated discussion regarding lung transplantation with all individuals with CF and an FEV1 less than 50% predicted

While many studies have demonstrated an association between forced expiratory volume in one second (FEV1) and mortality[8-14], FEV1 is an imperfect marker of disease severity. Survival with low lung function is improving, and some individuals with CF live for prolonged periods with severely reduced lung function while others die quickly following a decline in FEV1 [1, 8, 15]. Determining which FEV1 (best, worst, “baseline”, or during an exacerbation) should prompt action is challenging. Expert
consensus concluded that an FEV1 <50% predicted, regardless of the context, should prompt discussion of LTx as a potential therapeutic option (Figure 1). This discussion serves as an opportunity to identify barriers to LTx and to clarify the individual’s goals of care (See Table 3). Some potential barriers to LTx could require years of work to correct in order for an individual to become an acceptable candidate. Early discussion may permit this opportunity.

**Figure 1: Lung function thresholds for communication about lung transplantation and timing of lung transplant referral**

*In the presence of contraindications, recommend discussion with at least two transplant centers prior to determining that an individual is not a transplant candidate*

3. The CF Foundation recommends that the individual’s CF care team elicit and address CF-specific psychosocial and physical concerns about lung transplantation to facilitate transition to transplant

Numerous psychosocial, physical, and care-related concerns emerged from the focus group as being particularly salient among individuals with CF. Increased complexity of care, the potential for decentralization of care (leaving the CF center), worsening impairments in quality of life at a young age, the potential loss of CF identity, concerns regarding family planning, relationship issues, and education/career could influence their approach to the transplant process. There is decreased access to referral, listing and LTx for individuals with CF and lower socioeconomic status (e.g. Medicaid insurance status)[16, 17]. Geographic disparities in access to LTx are an important consideration for people with CF [16]. Although Hispanic individuals with CF tended to have milder phenotypes, a recent study demonstrated increased risk of death without LTx and a younger age at death for Hispanic individuals
with CF[18]. Providing support to individuals with CF during the transition requires an understanding of these (and other) CF-specific psychosocial concerns.

4. The CF Foundation recommends the use of up-to-date CF-specific transplant resources to promote understanding of the transplant journey and to minimize misconceptions regarding outcomes. Individuals with CF and their families should have access to contemporary, CF-specific information regarding LTx in order to optimize their understanding of potential transplant outcomes. These data can be found on the websites of several organizations, including the Cystic Fibrosis Foundation (CFF.org), the International Society for Heart and Lung Transplantation (ISHLT) (ishlt.org), and the Scientific Registry of Transplant Recipients (SRTR.org). Decision aids or other technology-based sources of information could be useful to highlight misconceptions/misunderstanding and facilitate an accurate fund of knowledge regarding LTx. Another potential resource is connecting people with CF with each other to address concerns regarding LTx[7].

5. The CF Foundation recommends the CF and lung transplant care teams acknowledge and provide support for mental health concerns regarding the referral and evaluation process for transplant that are unique to individuals with CF. Many focus group members noted that the idea of requiring LTx may elicit reflexive, internal attributions that the need for transplant reflects a failure of their own adherence behaviors. Because the importance of adherence-related behaviors is often underscored for many individuals with CF, and these behaviors are integrally tied to clinical functioning in younger individuals with CF, this implicit association may inadvertently elicit feelings of shame[19, 20] or stigma[21]. For example, many individuals in the focus group characterized coping styles that would ‘fight’ or ‘beat’ CF through vigilant adherence behaviors[22-24]. Providers are encouraged to identify and address individuals’ negative self-directed emotions because they can lead to avoidance of clinical interactions and delay the receipt of appropriate care[25, 26]. In addition, providers should be aware that the introduction of uncertainty about patients’ eligibility for LTx may serve to increase ambivalence and ultimately avoid transplant-related knowledge or health decisions [27, 28]. Moreover, depression and anxiety are common among individuals with CF[29] and may adversely impact LTx outcomes[30].

6. For individuals with CF 18 years of age and older, the CF Foundation recommends lung transplant referral no later than when:

- FEV₁ is <50% predicted and rapidly declining (>20% relative decline in FEV₁ within 12 months)
- OR
- FEV₁ is <40% predicted with markers of shortened survival (including, those noted in recommendation #10, 14, 15, 16, and 18)
- OR
• FEV1 is <30% predicted

Because FEV1 is associated with mortality[8-14], FEV1 thresholds were identified to prompt further action, including evaluation for markers of shortened survival (discussed below) and/or lung transplant referral. Markers of shortened survival include low FEV1, 6-minute walk test (6MWT) distance <400 meters, hypoxemia (SpO2 <88% or PaO2 <55 mmHg, at rest or with exertion), hypercarbia (Paco2 >50 mmHg, confirmed on arterial blood gas), pulmonary hypertension (PA systolic pressure >50 mmHg on echocardiogram or evidence of right ventricular dysfunction in the absence of a tricuspid regurgitant jet), BMI <18 kg/m2, increased frequency of pulmonary exacerbations (>2 exacerbations per year requiring IV antibiotics or one exacerbation requiring positive pressure ventilation), massive hemoptysis, or pneumothorax.

Although FEV1 alone should not determine timing of lung transplant referral, referral should occur no later than when the non-exacerbation (“stable”) FEV1 is <30% predicted. Among individuals with a “stable” FEV1 <30% predicted in the US, approximately 10% die without LTx each year after reaching this threshold[1]. For individuals with frequent exacerbations, it may be difficult to assess a “stable” FEV1, but these individuals may benefit from referral (see recommendation #15). Rapidly declining FEV1 has been shown to predict death without LTx[15, 31, 32]. A recent study of a sample of individuals with CF who died in the US found that 38% had a documented “highest” FEV1 that was greater than 40% in the year prior to death, highlighting that a rapid decline in FEV1 may precede death for many individuals with CF[33]. Recommendations 10, 14-16, and 18 identify individuals with risk profiles highlighted in published prognostic models[8, 10-14].

7. For individuals with CF under the age of 18 years, the CF Foundation recommends lung transplant referral when the FEV1 is <40% predicted

Individuals with CF frequently transition to adulthood with FEV1 in the normal or only mildly impaired range, with only 5% of 18 year olds having severe lung disease (FEV1 <40%) in 2015[34]. Children with CF tend to do worse than adults with the same FEV1 % predicted. For this reason, expert consensus was that children with CF under age 18 years should be referred for LTx at an earlier FEV1 threshold than the average adult individual [31]. For children with markers of increased disease severity (including those noted in recommendation 10, 14-16, and 18) consideration for referral prior to the FEV1 <40% threshold is recommended.

8. For individuals with CF and an FEV1 <40% predicted, the CF Foundation recommends an annual 6-minute walk test (6MWT), assessment of need for supplemental oxygen and venous blood gas to screen for markers of severe disease that may warrant transplant referral

The 6-minute walk test (6MWT) distance is used regularly in Canada, Ireland and other parts of the world to assess the clinical status of individuals with advanced/deteriorating CF lung disease[35, 36]. Expert consensus was that annual testing with a 6MWT, an assessment for supplemental oxygen requirement, and venous blood gas (VBG) would provide clinically meaningful data for patients with ALD. Assessment for supplemental oxygen requirement (SpO2 <88% or PaO2 <55 mmHg) should occur at rest, with exertion, and during sleep [8, 37-39]. An annual VBG should be used to screen for hypercarbia,
and if $P_{\text{CO}_2}$ is elevated ($P_{\text{CO}_2} > 56 \text{ mmHg}$), a confirmatory arterial blood gas (ABG) should be obtained. In the pediatric population, consider performing testing prior to reaching the FEV$_1 < 40\%$ threshold.

9. For individuals with CF 18 years of age and older with FEV$_1 < 40\%$ predicted, the CF Foundation recommends a baseline echocardiogram to screen for pulmonary hypertension.

Pulmonary hypertension is common in individuals with advanced CF-related lung disease [39-43], but its presence is rarely identified prior to evaluation for LTx. Repeat echocardiogram should be considered for individuals with worsening clinical status.

10. The CF Foundation recommends lung transplant referral, regardless of FEV$_1$, when there are markers of shortened survival, including:

- 6MWT distance < 400 meters
- OR
- hypoxemia (at rest or with exertion)
- OR
- hypercarbia ($P_{\text{CO}_2} > 50 \text{ mmHg}$, confirmed on arterial blood gas)
- OR
- pulmonary hypertension (PA systolic pressure > 50 mmHg on echocardiogram or evidence of right ventricular dysfunction in the absence of a tricuspid regurgitant jet)

Individuals with FEV$_1$ greater than 40$\%$ predicted are unlikely to have these data available unless their clinical status is out of proportion to their FEV$_1$.

The 6MWT distance is associated with death or LTx for individuals with CF [42, 44-46]. The ISHLT recommends referral for LTx evaluation when the 6MWT distance is less than 400 meters [47]. Although a sub-maximal exercise test for a majority of individuals with CF, the 6MWT is a marker of functional status and may better reflect limitations experienced by individuals with ALD than the FEV$_1$ alone.

Supplemental oxygen requirement and/or low $P_{\text{O}_2}$ have been repeatedly associated with death without LTx for individuals with CF [1, 8, 37, 42, 48, 49]. Arterial hypercarbia is a known predictor of death in individuals with CF [8, 12, 39, 50]. Pulmonary hypertension has been associated with death without lung transplant [51-53], but echocardiograms are imperfect at determining the severity of pulmonary hypertension in patients with ALD and may identify “false positive” cases [54, 55]. In an individual with FEV$_1 < 40\%$ whose only marker of increased disease severity is an elevated PA systolic pressure (>50 mmHg), a confirmatory right heart catheterization may be warranted prior to transplant referral.

11. The CF Foundation recommends that modifiable barriers to lung transplantation be addressed preemptively to optimize transplant candidacy; however, unresolved barriers should not preclude
referral. Potentially modifiable barriers may include but are not limited to: sputum microbiology, nutritional status, diabetes management, renal insufficiency, liver disease, adherence behaviors, mental health issues, substance use, and psychosocial factors.

The number of individuals with CF who die each year without lung transplant referral remains significant[1]. A survey of physicians in the US demonstrated that potentially modifiable barriers are a frequent reason for non-referral[56]. Modifiable barriers to transplant should be identified preemptively in CF clinic, potentially years prior to the need for LTx; these do not need to be fully resolved prior to a referral (Table 3). Transplant providers may help those individuals with modifiable barriers better understand how these issues negatively impact their transplant candidacy and provide tools and motivation to mitigate these barriers. The transplant program can assess potentially modifiable barriers in the context of transplant candidacy as a whole, to determine exactly what progress needs to be made in order for someone to become an acceptable candidate for transplant. Additionally, non-medical barriers to LTx, including insurance status, geography, finances, medical literacy, and limited social support, may influence not only when to refer for transplant, but also where to refer. Certain psychosocial factors may take years to optimize prior to a lung transplant referral.

12. The CF Foundation recommends CF clinician consultation with local and geographically distant lung transplant centers for individuals with microorganisms that may pose a risk for lung transplantation (e.g. Burkholderia cepacia complex, nontuberculous mycobacterium)

Infection with certain microorganisms (e.g. Burkholderia cepacia complex, nontuberculous mycobacterium, multi-drug resistant microorganisms) is associated with worse outcomes following lung transplantation[14, 47, 57-62]. These microorganisms may be considered absolute contraindications at some transplant programs and acceptable at other institutions. Similarly, infection with a particular organism may not in and of itself be considered an absolute contraindication by a program, but if combined with other risk factors, may be a reason an individual is declined for LTx.

13. The CF Foundation recommends consultation with at least two transplant centers before determining that an individual is not a transplant candidate

Each lung transplant program has its own criteria for transplant candidacy and listing. Criteria differ widely based on institutional experience, resources and risk thresholds. Center practices may also evolve over time. Individuals who are declined at one transplant center may be deemed suitable at another center.

14. The CF Foundation recommends lung transplant referral in adults with CF with a BMI <18 and FEV\textsubscript{1} <40% predicted while concurrently working to improve nutritional status

Studies have shown low BMI is a risk factor for death without lung transplantation[1, 10, 11, 14, 63, 64] and it should be considered a marker of urgency for lung transplant referral. Minimum BMI thresholds vary from center to center and low BMI should be proactively addressed (enteral tube feeding guidelines)[65] as a modifiable barrier to transplant. While a specific BMI cutoff is not useful for defining
malnutrition in the pediatric population and a weight-for-age >10th percentile is a common goal[66], malnutrition is an important modifiable barrier to lung transplantation for children with CF [67] and should be addressed concurrently with referral for children with ALD.

15. The CF Foundation recommends lung transplant referral of individuals with FEV1 <40% predicted and >2 exacerbations per year requiring IV antibiotics or 1 exacerbation requiring positive pressure ventilation regardless of FEV1.

Increasing number of pulmonary exacerbations is associated with death without transplant among individuals with ALD, with risk increased in the setting of 1 or more courses of IV antibiotics[1, 9, 13, 14, 68] or the need for hospitalization[10, 11, 13, 14, 37]. The presence of acute hypercapnic or hypoxic respiratory failure, or chronic hypercapnic respiratory failure, necessitating positive pressure ventilation (e.g. noninvasive or invasive ventilatory support), in the hospital or home setting, should prompt referral for LTx regardless of FEV1.

16. The CF Foundation recommends referral for lung transplant evaluation of individuals with FEV1 <40% predicted and massive hemoptysis (>240mL) requiring ICU admission or bronchial artery embolization.

Hemoptysis increases the risk for death or LTx [69, 70]. There may be an increased risk for hypercapnic respiratory failure and death following bronchial artery embolization among individuals with ALD[71]. It is expert consensus that among individuals with CF and FEV1 between 30% and 40% predicted, an episode of hemoptysis leading to ICU admission and/or bronchial artery embolization should prompt referral for LTx evaluation. Individuals referred for hemoptysis may have risk that is not captured in the lung allocation score (LAS), and serious hemoptysis may occur without warning, potentially prompting lung transplant centers to request an exception to the LAS. Additionally, individuals with CF and FEV1 >40% may also warrant LTx evaluation if episodes of hemoptysis are frequent and severe.

17. For women with CF, especially those who are younger or short stature, the CF Foundation recommends special consideration for lung transplant referral even when other thresholds have not been met.

There is a persistent gender gap in survival for individuals with CF[1, 8-11, 49, 72, 73] and this recommendation aims to focus providers on the increased risk of death for women with CF. Special consideration for LTx referral is recommended for women who are younger (age 18-25 years), have shorter stature (under 162 cm)[74], CF-related diabetes, rapidly declining FEV1, or rapidly declining BMI.

18. The CF Foundation recommends consideration of early lung transplant referral for individuals with FEV1 <40% predicted and pneumothorax.

The occurrence of pneumothorax is more frequent among individuals with CF and severe pulmonary impairment (FEV1 <40%) and older age, leading to an increased number of hospitalizations and number of days spent in the hospital, and an increase in 2-year mortality for individuals with this
complication[75]. Recurrent pneumothorax is an indication for referral for LTx in the ISHLT recommendations for individuals with CF[47]. This complication is a marker of increased disease severity, is associated with decreased survival, and may impact surgical planning for LTx.

19. The CF Foundation recommends that CF clinicians develop relationships with peers at partnering transplant centers to:

- optimize the transition to transplant, starting with referral
- understand transplant center-specific practices, including navigating complex socioeconomic barriers to transplant
- maintain ongoing dialogue about clinical status of individuals listed or approaching transplant listing

Identifying peers at partnering transplant centers allows for improved communication and facilitates continuity of care. CF care teams can deliver the best care to individuals at their home CF Center when they are aware of the partnering lung transplant center practices. Clear communication of the necessary medical information at the time of transplant referral will streamline the process and increase efficiency for both teams. Maintaining a relationship between the CF team and partnering transplant team is key to facilitate a smooth transplant referral and ongoing co-management of individuals in the pre-transplant phase. CF providers, including all members of the CF care team, can reinforce the importance of ongoing work by the individuals with CF and caregivers to address outstanding concerns.

20. The CF Foundation recommends communication between the CF and lung transplant care teams every 6 months and with major clinical changes to discuss individuals referred but not listed for transplant to review clinical status and progress addressing transplant team recommendations

Timely referral for LTx allows individuals with CF to establish a relationship with the transplant team, obtain transplant specific education, and identify and modify barriers to transplant. For individuals with CF deemed “too early” for listing, ongoing discussion at set time intervals will allow for continued assessment of disease progression (e.g. development of markers of increased disease severity noted in recommendation 10, 14-16, and 18; significant clinical events) and readiness for transplant. For individuals deferred due to barriers, dialogue should highlight progress toward addressing barriers to transplant. Further, because certain characteristics such as height, chest cavity size, ABO blood type and HLA sensitization may result in challenges finding a suitable donor, it is critical for the transplant team to be aware of changes in clinical status, which may affect transplant candidacy as well as timing for listing. Open lines of communication between the CF and lung transplant care teams regarding patients who are listed or approaching listing are vital if an individual has a sudden deterioration. Geographic and program-specific donor availability and waitlist times may influence the timing of listing. Finally, local lung transplant center practices will necessarily influence how CF providers interpret and implement these consensus recommendations.
21. The CF Foundation recommends research on factors contributing to lack of transplant referral for individuals with CF and FEV₁ <30% predicted or those with higher lung function who die of respiratory disease.

Evidence indicates that many individuals with CF who die from respiratory disease are never referred for transplant[2, 17]. Presumably, some deaths may have been prevented if LTx had been considered and a referral made. Available data suggests the reasons for non-referral may not be due to absolute contraindications to transplant[2]. More research is needed to understand why some individuals with ALD are not referred and which individuals are at greatest risk of dying without transplant referral.

4. International perspective

Outside of the U.S., there is a broadly similar experience with delays in referral for lung transplant. Both European and Australian CF patient registries show that many individuals die without receiving LTx. It is not known, however, whether these individuals were in the process of assessment or had been considered for transplant prior to death. It is likely that similar barriers to LTx seen in the U.S. exist in many countries and guidelines for timely referral for lung transplant assessment are welcome. In addition to the barriers outlined earlier in this statement, there are a number of unique challenges in Europe as many of the smaller European countries do not have a transplant program and must refer to neighboring countries. This leads to further barriers such as inability of very sick individuals to travel (often significant distances by air), language and cultural difficulties throughout the transplant process, and complexities of cross-country funding and follow-up. Even in countries with well-established programs, many individuals with CF die without receiving LTx [2]. In the UK, in a recent survey of 28 specialty CF centers[76] 22% of respondents expressed concerns that LTx was discussed with patients too late and 19% expressed concerns that individuals with CF were referred for transplant assessment too late. Barriers to referral in the UK included patient refusal, poor-adherence and psychological readiness as well as unexpected rapid clinical deterioration or the presence of significant comorbidities/infections that could preclude transplant. In France, with a well-developed National Lung Transplant Program, including the introduction of an emergency transplant program in 2007, 50% of all CF deaths occur without lung transplantation of which 72% had at least one indication for transplant and were not on the active transplant list [2]. Although the majority of these individuals were in the process of lung transplant assessment or had been declined for LTx, 39% of these potentially eligible individuals with CF had never been considered for transplant[2]. A subsequent survey of French centers[77] proposed an earlier structured approach to transplant assessment including improved patient and caregiver education and earlier discussions of transplant options. These studies, in countries with well-established transplant programs and specialized CF centers, highlight that transplant referral challenges are worldwide and that barriers to early referral need to be identified and overcome.

5. Conclusions and next steps

Survival for individuals with CF has improved dramatically over the past few decades and this improvement may accelerate with new agents that address the cellular defect in CF. Nevertheless, the majority of individuals with CF still eventually succumb to their lung disease. LTx has the potential to extend survival. Despite this fact, many individuals with CF die without ever being considered for
transplantation. These guidelines are intended to help CF providers appropriately counsel their patients about LTx. The journey through referral, evaluation, listing and transplantation is fraught with physical and psychosocial challenges for the individual and their family. It is the responsibility of both the CF team and the transplant team to provide support through this transition. Many of the barriers to LTx can be overcome if identified and addressed early enough in the course of the disease to permit adequate time for resolution. While data is limited, there is a growing body of literature to support the use of FEV₁ combined with other physiologic parameters including pulmonary artery pressure, hypoxia, hypercarbia, trajectory of lung function and nutritional status to determine appropriate timing of referral.
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>% Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong> The CF Foundation recommends clinician-led efforts to normalize lung transplant as a component of clinical care through discussions regarding disease trajectory and treatment options including lung transplantation during annual visits in clinic</td>
<td>100%</td>
</tr>
<tr>
<td><strong>2</strong> The CF Foundation recommends CF care team initiated discussion regarding lung transplantation with all individuals with CF and an FEV\textsubscript{1} less than 50% predicted</td>
<td>100%</td>
</tr>
<tr>
<td><strong>3</strong> The CF Foundation recommends that the individual’s CF care team elicit and address CF-specific psychosocial and physical concerns about lung transplantation to facilitate transition to transplant</td>
<td>100%</td>
</tr>
<tr>
<td><strong>4</strong> The CF Foundation recommends the use of up-to-date CF-specific transplant resources to promote understanding of the transplant journey and to minimize misconceptions regarding outcomes</td>
<td>100%</td>
</tr>
<tr>
<td><strong>5</strong> The CF Foundation recommends the CF and lung transplant care teams acknowledge and provide support for mental health concerns regarding the referral and evaluation process for transplant that are unique to individuals with CF</td>
<td>100%</td>
</tr>
</tbody>
</table>
| **6** For individuals with CF 18 years of age and older, the CF Foundation recommends lung transplant referral no later than when:  
  - FEV\textsubscript{1} is <50% predicted and rapidly declining (>20% relative decline in FEV\textsubscript{1} within 12 months)  
  - FEV\textsubscript{1} is <40% predicted with markers of shortened survival (including, those noted in recommendation #10, 14, 15, 16, and 18)  
  - FEV\textsubscript{1} is <30% predicted | 100% |
<p>| <strong>7</strong> For individuals with CF under the age of 18 years, the CF Foundation recommends lung transplant referral when the FEV\textsubscript{1} is &lt;40% predicted | 100% |
| <strong>8</strong> For individuals with CF and a FEV\textsubscript{1} &lt;40% predicted, the CF Foundation recommends an annual 6-minute walk test (6MWT), assessment of need for supplemental oxygen and venous blood gas to screen for markers of severe disease that may warrant transplant referral | 100% |
| <strong>9</strong> For individuals with CF 18 years of age and older with FEV\textsubscript{1} &lt;40% predicted, the CF Foundation recommends a baseline echocardiogram to screen for pulmonary hypertension | 100% |</p>
<table>
<thead>
<tr>
<th></th>
<th>The CF Foundation recommends lung transplant referral, regardless of FEV$_1$, when there are markers of shortened survival, including:</th>
</tr>
</thead>
</table>
| 10 | - 6MWT distance <400 meters  
- hypoxemia (at rest or with exertion),  
- hypercarbia (PaCO$_2$ >50 mmHg, confirmed on arterial blood gas),  
- pulmonary hypertension (PA systolic pressure >50 mmHg on echocardiogram or evidence of right ventricular dysfunction in the absence of a tricuspid regurgitant jet) |
|   | The CF Foundation recommends that modifiable barriers to lung transplantation be addressed preemptively to optimize transplant candidacy; however, unresolved barriers should not preclude referral. Potentially modifiable barriers may include but are not limited to: sputum microbiology, nutritional status, diabetes management, renal insufficiency, liver disease, adherence behaviors, mental health issues, substance use, and psychosocial factors |
| 11 | The CF Foundation recommends consultation with at least two transplant centers before determining that an individual is not a transplant candidate |
| 12 | The CF Foundation recommends CF clinician consultation with local and geographically distant lung transplant centers for individuals with microorganisms that may pose a risk for lung transplantation (e.g. Burkholderia cepacia complex, nontuberculous mycobacterium) |
| 13 | The CF Foundation recommends lung transplant referral in adults with CF, with a BMI <18, and FEV$_1$ <40% predicted, while concurrently working to improve nutritional status |
| 14 | The CF Foundation recommends lung transplant referral of individuals with FEV$_1$ <40% predicted and >2 exacerbations per year requiring IV antibiotics or 1 exacerbation requiring positive pressure ventilation regardless of FEV$_1$ |
| 15 | For women with CF, especially those who are younger or short stature, the CF Foundation recommends special consideration for lung transplant referral even when other thresholds have not been met |
| 16 | The CF Foundation recommends consideration of early lung transplant referral for individuals with FEV$_1$ <40% predicted and pneumothorax |
| 19 | The CF Foundation recommends that CF clinicians develop relationships with peers at partnering transplant centers to:  
• optimize the transition to transplant, starting with referral  
• understand transplant center-specific practices, including navigating complex socioeconomic barriers to transplant  
• maintain ongoing dialogue about clinical status of individuals listed or approaching transplant listing | 100% |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>The CF Foundation recommends communication between the CF and lung transplant care teams every 6 months and with major clinical changes to discuss individuals referred but not listed for transplant to review clinical status and progress addressing transplant team recommendations</td>
<td>100%</td>
</tr>
<tr>
<td>21</td>
<td>The CF Foundation recommends research on factors contributing to lack of transplant referral for individuals with CF and FEV₁ &lt;30% predicted or those with higher lung function who die of respiratory disease</td>
<td>100%</td>
</tr>
</tbody>
</table>
Table 2: Focus group-derived themes and considerations for communication with individuals with cystic fibrosis

<table>
<thead>
<tr>
<th>Thematic Domain</th>
<th>Provider Exemplars from Focus Group</th>
<th>Effective Alternative Exemplars for Clinicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normalizing the need for lung transplantation</td>
<td>- ‘We will think about transplant when it’s time [for transplant]’</td>
<td>- ‘Transplant is often considered as a next step as CF worsens.’</td>
</tr>
<tr>
<td></td>
<td>- ‘Transplant is to be avoided if at all possible.’</td>
<td>- ‘Many -individuals with CF will undergo transplant as a component of their care when other therapies no longer work.’</td>
</tr>
<tr>
<td></td>
<td>- ‘You’re trading one disease for another.’</td>
<td>- ‘What have other providers told you, if anything, about the risks and benefits of transplant?’</td>
</tr>
<tr>
<td></td>
<td>- ‘You’ve fought hard and done your part. For most people living with CF, lung function will eventually worsen to the point where we consider transplant, no matter how hard you fight.’</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- ‘Your test results indicate we need to move forward with a transplant referral. We will set up your appointments.’</td>
<td>- ‘We did the best we could and now need to consider transplant as the next step to best treat your CF.’</td>
</tr>
<tr>
<td>Eliciting and addressing CF-related concerns</td>
<td>-‘Your lungs have failed you.’</td>
<td></td>
</tr>
<tr>
<td>and outcomes</td>
<td>-‘We [treatment team] have failed you.’</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-‘You fought hard but lost the battle.’</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-‘Your test results indicate we need to move forward with a transplant referral. We will set up your appointments.’</td>
<td></td>
</tr>
</tbody>
</table>
| Addressing transplant-related expectations | - ‘Most people have some concerns about transplantation. Help me to understand yours.’  
- ‘Your test results suggest that we may need to consider a transplant evaluation. What thoughts do you have, if any, about that possibility?’ |
| - ‘Recipients only live 5 years.’  
- ‘Many patients don’t do well after transplant.’  
- ‘Transplant is a death sentence.’ | - ‘Everyone’s transplant experience is different and unique. For people with CF the median post-transplant survival is almost 9 years. That means that half of the people who undergo lung transplantation for CF live for more than 9 years, many significantly more.’  
- ‘Individuals with CF who receive lung transplants show the greatest health and quality of life benefits compared to other lung transplant recipients. Although there are potential complications, the vast majority are manageable.’ |
| At diagnosis of CF and throughout the life-span | - Individuals with CF should establish and maintain care with a physician trained in the natural history, prognosis, and treatment options for CF  
- Discuss lung transplantation early in the course of disease as a means to normalize this component of clinical care. Introduce it as a potential treatment option that prolongs life for individuals with CF  
- Frame lung transplantation in a positive manner, instead of as a “last resort” or “failure of therapy,” because care team attitudes affect willingness to discuss lung transplantation when it becomes medically necessary for individuals with CF  
- Utilize up-to-date, CF specific, resources when providing lung transplant outcomes information |
|---|---|
| When lung function declines to FEV$_1$ <50% predicted | - Discuss values and goals of care  
- Implement all indicated medical therapies to optimize lung function and overall health  
- Discuss ways to optimize health/lung function to delay lung transplantation, and the importance of adherence pre- and post-transplant  
- Optimize BMI with appropriate nutrition interventions  
- Initiate discussion regarding lung transplantation; early discussion gives individuals with CF time to consider lung transplantation when it is not urgently needed  
- Note that lung transplant referral is not an event, it is a process that begins with informed discussions of benefits, risks, indications, and contraindications  
- Elicit and address CF-related concerns about lung transplantation, such as: fear, shame, and giving up the “fight” against CF  
- Explain the logistics of lung transplantation at the “home” CF Center  
- Assess for potential barriers to transplant: medical, psychosocial, financial  
- Discuss potential geographic barriers to lung transplant (e.g. potential need to relocate, distance to travel for evaluation, insurance limitations to lung transplant center options for coverage)  
- Acknowledge differences in clinical outcomes and the potential need for increased support for individuals with disadvantaged backgrounds |
| When lung function declines to FEV$_1$ <40% predicted | - Increase frequency of CF clinic visits, if indicated, to address contributing factors  
- Emphasize the importance of nutrition, diabetes control, physical conditioning, self-care, mental health, adherence, and social support and correlate them with clinical outcomes and implications for candidacy for transplant |
- Evaluate for markers of shortened survival using 6-minute walk test, oxygen desaturation study, nocturnal oximetry, blood gas, echocardiogram
- Assess for organisms with implications on transplant candidacy (such as: NTM, fungus, and Burkholderia species)
- **Referral for individuals with markers of increased severity of disease** (e.g. 6-minute walk test distance <400 meters, supplemental oxygen requirement, arterial hypercarbia, pulmonary hypertension). Discuss implications for decreased survival in the presence of markers of increased severity of disease as the rationale for referral to consider lung transplantation
- **Referral for all individuals under 18 years of age**

| When lung function declines to FEV$_1$ <30% predicted | - **Referral for all individuals**  
- Continue at least annual monitoring for markers of shortened survival. Individuals with CF can have prolonged survival with FEV$_1$ <30% predicted, but it is important to continue monitoring for complications of CF that increase the risk of death without lung transplant  
- Update the local transplant center every 6 months or with clinical changes |
| Modifiable barriers to lung transplantation | - Malnutrition (BMI less than 17 kg/m$^2$) may be a contraindication to lung transplantation, but is modifiable. As lung disease progresses, malnutrition becomes more prevalent. Recommend use of enteral tube feed guidelines for management of malnutrition  
- CF-related diabetes can be associated with increased pulmonary exacerbations, weight loss, and lung function decline. Suboptimal management of diabetes may be a marker of non-adherence and treatment could slow disease progression. Diabetes control should be optimized to maximize medical management of advanced CF and minimize transplant-associated risk  
- Chronic narcotic use may impair post-lung transplant pain management and may be a contraindication at certain centers  
- Substance use has been associated with worse post-transplant outcomes and there are center-specific rules related to substance use  
- Promote strategies to optimize adherence, as many transplant centers consider non-adherence a relative (and sometimes absolute) contraindication to listing/transplant  
- Early referral permits education and contract setting, if needed, and an opportunity to assess for capacity for adherence  
- Anxiety and depression are prevalent in individuals with CF, and become more prevalent with advanced lung disease and can impair recovery from transplant. Identify and treat mental health issues that may negatively impact transplant candidacy and outcomes |
- Address psychosocial barriers such as: caregiver support, finances, and health literacy

**Special considerations**

- Geographic and program-specific donor availability may influence the timing of listing and choice of transplant center
- Insurance coverage may limit access to specific transplant centers
- Complexity of surgical procedure may influence the choice of transplant center
- Center-specific practices are dynamic and may change over time

*The following may impact lung transplantation candidacy depending on transplant center-specific practices:*

- Certain infections (*Burkholderia cenocepacia*, *Burkholderia gladioli*, *Burkholderia dolosa*, *Mycobacterium abscessus*, *Scedosporium prolificans*)
- Renal insufficiency
- Liver disease
- Critical or unstable clinical condition (e.g. mechanical ventilation or ECMO)
- Cardiac dysfunction
- Prior thoracic surgery
- Prior lung transplantation
- History of cancer

**Decision to initiate lung transplant referral**

- It is important not to rely solely on the FEV₁ for timing of referral. Incorporate other markers of shortened survival into the referral decision: hypoxemia, hypercarbia, shortened 6-minute walk test distance, increasing frequency/severity of exacerbations, low BMI, pulmonary hypertension, massive hemoptysis, pneumothorax, female sex, and short stature
- Refer early to avoid missing the lung transplant window
- Refer early to give opportunity to explore other options if first transplant center declines the individual as a candidate
- Provide detailed information about clinical history, markers of disease severity, and potential contraindications.
- The balance of independence versus the need for social support is especially complex for adolescents and young adults
- Acknowledge the stress, expense, invasiveness of procedures (e.g. colonoscopy, right heart catheterization), and waiting involved with referral and evaluation
- Discuss insurance and financial implications
- Assess geographic barriers to transplantation and identify transplant center where individual has the most social support
- When a referral is “early,” it is an opportunity to get detailed information about transplant and serves as a second opinion that could identify important modifiable barriers to eventual transplantation
| Decision to defer listing | - Referral during a crisis, or rapid decline, may limit an individual’s access to transplant depending on local transplant center practices
- Consult at least two lung transplant centers prior to determining that an individual is not a transplant candidate if the first center declines to list the individual because of a contraindication
- If an individual is “too early” for listing, then establish a plan for continued monitoring and communication with the transplant team
- Continued communication with the transplant center includes information about changes in clinical status, social situation, and goals of care |

| Decision to list for transplant | - Communicate with the transplant center about changes in the individual’s status while listed
- Lung Allocation Score (LAS) is used for determining lung transplant recipient priority in the US. Important components of the LAS include: age, FVC, pCO₂, oxygen requirement, BMI, 6MWT distance, pulmonary arterial pressure, presence of diabetes, diagnosis, and functional status
- Continue to acknowledge the stress, expense, waiting time, and uncertainty for individuals awaiting lung transplant |
**The CF Lung Transplant Referral Guideline Committee:**

Kathleen J. Ramos - Chair

Jordan M. Dunitz - Chair

Daniel B. Rosenbluth

Daniel J. Dorgan

Alice L. Gray

George Mallory

Patrick J. Smith

Martha Markovitz

Melinda Solomon

Erin L. Mahoney

Amy Lucy

John R. McArdle

Joseph M. Pilewski

Albert Faro

Erin Tallarico

Sarah E. Hempstead
References


77. A DVPAP-BDKRKLMMR: WS18.4 Evaluation of transplantation information delivered to patients and their relatives by the professionals from cystic fibrosis centres and transplant centres and from transplanted peer-patients in France. *Journal of Cystic Fibrosis* 2018, 17:S33-34.